VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021

October, 28 2021

BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details: Wednesday, November 10th @ 8:30am Eastern Time Toll Free: 855-327-6837 International: 631-891-4304 Conference ID: 10017178 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1512469&tp_key=ee68066700 DOWNLOAD: 2021 Q3 VYN201 Earnings_Presentation About VYNE Therapeutics Inc. VYNE’s mission is to improve…

Read More

Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies

October, 26 2021

VYN201 exhibits anti-inflammatory effect in preclinical data similar to a super-potent glucocorticosteroid VYN201 appeared well-tolerated in mice, as seen through animal body weight and skin condition VYN201 also demonstrates stronger inhibition of key Th17 cytokines in ex vivo data with human skin tissue when directly compared to JAK1/2 inhibitor, ruxolitinib BRIDGEWATER, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced preclinical data showing that its pan-bromodomain and extra-terminal (“BET”) inhibitor, VYN201, significantly reduced the expression of several key pro-inflammatory cytokines relevant to Th17-mediated autoimmune diseases in an animal model and an…

Read More

VYNE Therapeutics Announces Formation of Scientific Advisory Board

October, 21 2021

Renowned Experts to Support VYNE’s Strategy of Developing Novel Treatments for Immunological and Inflammatory diseases SAB to Help Guide Clinical Development of VYNE’s BET Inhibitor Drug Candidates BRIDGEWATER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the formation of its Scientific Advisory Board (SAB) composed of leading scientists and clinicians specializing in immunological and inflammatory diseases. The SAB will provide scientific expertise and guidance to the VYNE management team and Board as the Company progresses its pipeline of innovative treatments for immuno-inflammatory conditions. These include the novel class of bromodomain…

Read More

VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

October, 19 2021

Important milestone achieved as part of the Company’s new corporate strategy to develop treatments for immuno-inflammatory diseases Topline results anticipated in early Q1 2022 BRIDGEWATER, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has enrolled the first patient in its Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD). FMX114 is VYNE’s proprietary investigational combination gel formulation of tofacitinib and fingolimod. The product is being developed to address both the source and cause of inflammation in AD by developing a distinct combination of…

Read More